Release of Health Canada’s guidance for stakeholders: Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products
Various Publications under the Chemicals Management Plan
Period Reduced for Keeping Clinical Trial Records for Drugs and Natural Health Products
REMINDER National Consultations on Supply Chain Transparency, including Labelling
Drug Submission Performance Quarterly Reports (October-December 2021): TPD, BRDD & NNHPD
Blue Box Processor Registration Opening Soon
RPRA approves Stewardship Ontario’s Simplified Steward Fee-setting Methodology Proposal with Conditions
Environment and Climate Change Canada – Mandatory Labelling for Chemicals in Consumer Products
Draft Screening Assessment – Substances Identified as Being of Low Concern
Proposed Environmental Performance Agreement for the Formulation of Chlorhexidine Products Published
